Candel director granted 2,199 stock options
Candel Therapeutics director Paul B. Manning received a grant of stock options as compensation.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Candel Therapeutics director Paul B. Manning received a grant of stock options as compensation. He was awarded options to buy 2,199 shares of common stock at an exercise price of $10.30 per share. The award replaces normal quarterly cash payments and is fully vested at the time of grant, leaving him with 2,199 derivative securities after this transaction.
Insider Trade Summary
Grant/Award: 2,199 shares
Grant/Award
1 txn
Insider
Manning Paul B
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 2,199 | $8.639 | $19K |
Holdings After Transaction:
Stock Option (Right to Buy) — 2,199 contracts (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 0 to 2,199 contracts (Direct)
Footnotes (1)
- F1. This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.
Key Figures
Options granted: 2,199 options
Exercise price: $10.30 per share
Post-grant derivative holdings: 2,199 derivative securities
+2 more
5 metrics
Options granted
2,199 options
Stock Option (Right to Buy) grant to director
Exercise price
$10.30 per share
Exercise price for granted stock options
Post-grant derivative holdings
2,199 derivative securities
Total options held after this grant
Grant date
June 30, 2026
Option award transaction date
Expiration date
June 30, 2036
Option expiration if not exercised
Key Terms
Stock Option (Right to Buy), exercise price, fully vested, in lieu of normal quarterly cash payments
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "10.3000" as the exercise price per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested financial
"The underlying award quantity is fully vested at time of grant."
in lieu of normal quarterly cash payments financial
"This award has been granted in lieu of normal quarterly cash payments."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Candel Therapeutics (CADL) director Paul B. Manning report in this Form 4?
Paul B. Manning reported receiving a grant of stock options for 2,199 shares of Candel Therapeutics common stock. These options are a form of equity compensation and are documented as an acquisition transaction on the Form 4.
How many Candel Therapeutics (CADL) stock options did Paul B. Manning receive?
He received stock options covering 2,199 shares of Candel Therapeutics common stock. This grant increases his derivative holdings by that amount, reflecting additional potential future ownership if the options are exercised.
What is the exercise price of Paul B. Manning’s Candel Therapeutics (CADL) options?
The options have an exercise price of $10.30 per share. This means Manning can purchase Candel Therapeutics common stock at $10.30 per share if he exercises the options before they expire.
When do Paul B. Manning’s Candel Therapeutics (CADL) stock options vest and expire?
The award is fully vested at the time of grant, according to the footnote. The options are scheduled to expire on June 30, 2036 if they are not exercised by that expiration date.
Why was Paul B. Manning granted stock options instead of cash by Candel Therapeutics (CADL)?
The footnote explains the award was granted in lieu of normal quarterly cash payments. This indicates Candel Therapeutics chose to compensate Manning with equity-based awards rather than customary cash compensation for that period.
How many derivative securities does Paul B. Manning hold in Candel Therapeutics (CADL) after this grant?
Following this transaction, Manning holds 2,199 derivative securities related to Candel Therapeutics. These represent the stock options granted in this filing and show his post-transaction derivative position from this award.
AI-generated analysis. How Rhea-AI works. Not financial advice.
